OpGen (OPGN) vs. Rosetta Genomics (NASDAQ:ROSG) Head-To-Head Survey

Rosetta Genomics (NASDAQ: ROSG) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

7.5% of Rosetta Genomics shares are owned by institutional investors. Comparatively, 11.8% of OpGen shares are owned by institutional investors. 17.4% of OpGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Rosetta Genomics and OpGen, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rosetta Genomics 0 1 0 0 2.00
OpGen 0 0 2 0 3.00

OpGen has a consensus target price of $1.00, suggesting a potential upside of 455.56%. Given OpGen’s stronger consensus rating and higher probable upside, analysts clearly believe OpGen is more favorable than Rosetta Genomics.


This table compares Rosetta Genomics and OpGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rosetta Genomics N/A N/A N/A
OpGen -533.47% -1,289.51% -234.78%

Earnings and Valuation

This table compares Rosetta Genomics and OpGen’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rosetta Genomics $9.23 million 0.37 -$16.23 million N/A N/A
OpGen $4.03 million 2.52 -$19.16 million ($0.51) -0.35

Rosetta Genomics has higher revenue and earnings than OpGen.


OpGen beats Rosetta Genomics on 6 of the 11 factors compared between the two stocks.

About Rosetta Genomics

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

About OpGen

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply